Prudential Financial Inc. lessened its stake in Viewray Inc (NASDAQ:VRAY) by 26.3% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 333,530 shares of the company’s stock after selling 119,310 shares during the quarter. Prudential Financial Inc.’s holdings in Viewray were worth $2,938,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Marshall Wace LLP grew its position in Viewray by 47.1% in the 1st quarter. Marshall Wace LLP now owns 131,179 shares of the company’s stock valued at $970,000 after buying an additional 42,015 shares in the last quarter. Asymmetry Capital Management L.P. lifted its holdings in Viewray by 431.0% in the 2nd quarter. Asymmetry Capital Management L.P. now owns 443,973 shares of the company’s stock valued at $3,911,000 after acquiring an additional 360,362 shares during the last quarter. Penn Capital Management Co. Inc. lifted its holdings in Viewray by 6.0% in the 1st quarter. Penn Capital Management Co. Inc. now owns 554,892 shares of the company’s stock valued at $4,101,000 after acquiring an additional 31,327 shares during the last quarter. Envestnet Asset Management Inc. lifted its holdings in Viewray by 224.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 41,009 shares of the company’s stock valued at $361,000 after acquiring an additional 28,380 shares during the last quarter. Finally, Royce & Associates LP lifted its holdings in Viewray by 7.8% in the 1st quarter. Royce & Associates LP now owns 498,900 shares of the company’s stock valued at $3,687,000 after acquiring an additional 35,900 shares during the last quarter.
In other news, CEO Scott William Drake acquired 131,260 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The shares were purchased at an average price of $3.81 per share, for a total transaction of $500,100.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Shahriar Matin acquired 60,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The stock was purchased at an average price of $4.02 per share, for a total transaction of $241,200.00. The disclosure for this purchase can be found here. Insiders sold 306,175 shares of company stock valued at $1,235,805 over the last three months. 15.48% of the stock is owned by insiders.
Shares of NASDAQ VRAY traded down $0.21 during mid-day trading on Monday, reaching $3.60. The company had a trading volume of 59,878 shares, compared to its average volume of 1,754,437. The stock has a fifty day moving average of $5.25 and a two-hundred day moving average of $7.54. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.01 and a current ratio of 4.01. The company has a market capitalization of $381.12 million, a price-to-earnings ratio of -3.71 and a beta of 1.06. Viewray Inc has a 12-month low of $2.76 and a 12-month high of $10.44.
Viewray (NASDAQ:VRAY) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.09). The company had revenue of $30.17 million during the quarter, compared to analysts’ expectations of $25.92 million. Viewray had a negative return on equity of 67.02% and a negative net margin of 128.13%. Viewray’s revenue for the quarter was up 83.5% compared to the same quarter last year. During the same period last year, the company earned ($0.30) earnings per share. Sell-side analysts forecast that Viewray Inc will post -1.18 earnings per share for the current fiscal year.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Want to see what other hedge funds are holding VRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viewray Inc (NASDAQ:VRAY).
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.